Lymphoma Clinical Trials in Baltimore

Showing 281-300 of 343 trials

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

NCT00085150

RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed or refractory leukemia or lymphoma.

LeukemiaLymphoma

National Cancer Institute (NCI)40 participantsStarted Apr 2004

Atlanta, Georgia, United States • Baltimore, Maryland, United States • Bethesda, Maryland, United States +2 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

NCT00809276

The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

LymphomaMultiple MyelomaLeukemia+1 more

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins92 participantsStarted May 2009

Baltimore, Maryland, United States • Houston, Texas, United States • Seattle, Washington, United States

COMPLETEDPHASE3< 1 mile

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

NCT00005578

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without dexrazoxane in treating children who have Hodgkin's disease.

Cardiac ToxicityLymphoma

Children's Oncology Group219 participantsStarted Mar 1997

Birmingham, Alabama, United States • Mobile, Alabama, United States • Little Rock, Arkansas, United States +60 more locations

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Lymphoma Trials in Other Cities

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Other Conditions in Baltimore